Biocon raises ₹4,150 crore through QIP; shares down 3% in a month

The initiative saw the issuance of 112,664,585 equity shares of face value ₹5 each to eligible qualified institutional buyers at the issue price of ₹368.35 per share, the Bengaluru-based firm said in a regulatory filing.

The QIP, which opened on January 12 and closed on January 14, attracted strong investor interest from a broad mix of domestic and international participants, reflecting robust confidence in the company's growth prospects, it added.

The proceeds from the QIP will be primarily utilised to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Ltd, including repayment of debt availed in this regard, Biocon said.

The company recently announced its board has approved a strategic corporate action to acquire all remaining minority shareholdings, including Viatris' stake, thereby making Biocon Biologics a wholly owned subsidiary.

The integration marks a pivotal step in Biocon's journey to lead in the therapeutic areas of diabetes, oncology, and immunology through a differentiated portfolio of biosimilars, insulins, generics, and peptides (GLP-1s), it stated.

The integration process is expected to be completed no later than March 31, 2026, it added.

Biocon Q2 earnings

Biocon had posted a consolidated net profit of ₹85 crore in the second quarter ended September 30. The company had reported a net loss of ₹16 crore in the July-September quarter of last fiscal.

Its revenue from operations rose to ₹4,296 crore in the second quarter as against ₹3,590 crore in the year-ago period.

Biocon share price

On Wednesday, Biocon shares had settled at ₹378.90 apiece, rising 0.42% on NSE. In the last five trading sessions, the stock has gained 1.17%, while it has fallen 3% over a month’s time.

Shares of Biocon hit a 52-week high of ₹424.95 on November 18, 2025, and a 52-week low of ₹291 on March 3, 2025. It's market capitalisation stood at ₹57,147.33 crore.